Address: 2 Eastman Way, Stevenage, Hertfordshire, SG1 4SZ,United Kingdom

Tel: +44 (0) 1438 737630

Web: http://www.arrowgenerics.co.uk/

Company description

Watson Pharmaceuticals Inc. (NYSE: WPI) entered the UK market in 2009 when it acquired the Arrow Group. Watson is a leading integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, brand and biologic pharmaceutical products. Watson is among the top five pharmaceutical companies in the United States, based on total prescriptions, and the fourth largest generics pharmaceutical company in the world. The company has commercial operations in many of the world’s established and emerging international markets. Watson’s largest commercial market is the United States, followed by key international markets including France, UK, Canada and Brazil.

Watson has three businesses in the UK.

Arrow No 7 is the base for the Group’s European headquarters in London.

Arrow Generics UK covers a wide range of therapeutic areas including standard and modified release presentations of tablets and capsules. The range does not stop there however and includes specialised presentations of creams, ointments, drops, suspensions, syrups, solutions and suspensions for nebulisation.

With a large emphasis within the Group being concentrated on the development of future patent expiring molecules, Arrow in the UK has benefited from the launch of numerous products on day ‘one’ following patent expiry. This continues to be the key strategy for the management team, many of whom have extensive experience of the generics industry.

Eden Biodesign is designated as Watson’s Centre of Excellence for Biologics, delivering process and product development; cGMP manufacturing of biologics and quality/regulatory expertise from a custom-designed facility located in Liverpool, UK.

With well over a decade of experience in producing a wide range of complex biopharmaceuticals, Eden Biodesign provides Watson with a strong foundation for establishing a leadership position in global biologics.

Eden Biodesign is currently developing biosimilar versions of complex biopharmaceuticals, such as recombinant Follicle Stimulating Hormone (rFSH) which was in-licensed in July 2010.

Products and services

For more information on products and services please visit http://www.arrowgenerics.co.uk or http://www.edenbiodesign.com/.